New Delhi: After Thrombosis with Thrombocytopenia Syndrome (TTS), it has now been found that British-Swedish pharma giant AstraZeneca’s COVID-19 vaccine, made in collaboration with Oxford University can raise the risk of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) , a rare but fatal blood clotting disorder, claimed researchers. While not new, VITT emerged as a new disease following adenovirus vector-based Oxford-AstraZeneca vaccine sold as Covishield in India and Vaxzevria in Europe at the height of the COVID pandemic in 2021, IANS reported.
“An unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4)” was found as the reason for VITT.
In separate research in 2023, scientists from Canada, North America, Germany and Italy described a virtually identical disorder with the same PF4 antibody that was fatal in some cases after natural adenovirus (common cold) infection.
Surat: Konark Suryas Odisha (KSO) are bracing up for their next challenge in the Legends…
Bhubaneswar: Cockroach omelette! How repulsive does that sound? Imagine the plight of the Air India…
Bargarh: A man was allegedly hacked to death over old rivalry in Odisha's Bargarh district…
Bhubaneswar: Ollywood superstar Sabyasachi Mishra has put on nearly 25 kg for his upcoming film…
Berhampur: To enhance workforce skills and ensure meter integrity, TP Southern Odisha Distribution Limited (TPSODL)…
Bhubaneswar: The nursing staff of government hospitals in Odisha have agreed to call off their…
New Delhi: Union Agriculture & Farmers Welfare Minister Shivraj Singh Chouhan on Saturday laid the…
New Delhi: As Israel continued their attacks on Lebanon for the fifth day, they managed to…